Clinical Trials Logo

Advanced Malignancies clinical trials

View clinical trials related to Advanced Malignancies.

Filter by:

NCT ID: NCT03717103 Completed - Clinical trials for Advanced Malignancies

A Phase 1 Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI188 in Advanced Malignancies

Start date: January 10, 2019
Phase: Phase 1
Study type: Interventional

This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy in patients with advanced malignancies.

NCT ID: NCT03297424 Completed - Solid Tumor Clinical Trials

A Study of PLX2853 in Advanced Malignancies.

Start date: September 12, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with advanced malignancies.

NCT ID: NCT03241173 Completed - Clinical trials for Advanced Malignancies

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

Start date: October 9, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01949 when given in combination with immune therapies in participants with advanced or metastatic malignancies.

NCT ID: NCT03158272 Completed - Clinical trials for Advanced Malignancies

A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread

Start date: May 25, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether an investigational immuno-therapy, cabiralizumab in combination with nivolumab, is safe and tolerable in the treatment of advanced malignancies.

NCT ID: NCT03126110 Completed - Metastatic Cancer Clinical Trials

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Start date: April 25, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.

NCT ID: NCT02923349 Completed - Metastatic Cancer Clinical Trials

A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors

Start date: October 31, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and tolerability and assess preliminary efficacy of INCAGN01949 in subjects with advanced or metastatic solid tumors.

NCT ID: NCT02737501 Completed - Lung Cancer Clinical Trials

ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants

ALTA-1L
Start date: May 26, 2016
Phase: Phase 3
Study type: Interventional

The purpose of the study is to compare the efficacy of brigatinib to that of crizotinib in ALK+ locally advanced or metastatic non-small cell lung cancer (NSCLC) participants naive to ALK inhibitors, as evidenced by progression-free survival (PFS).

NCT ID: NCT02697591 Completed - Metastatic Cancer Clinical Trials

A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors

Start date: June 20, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

This was an open-label, non-randomized Phase 1/2 safety study of INCAGN01876 in participants with advanced or metastatic solid tumors that was conducted in 2 parts. Part 1 is dose escalation and safety expansion which determines the optimal dose and maximum number of tolerated doses. Part 2 is dose expansion in which Part 1 recommended dose will be evaluated.

NCT ID: NCT02678260 Completed - Clinical trials for Advanced Malignancies

Phase I Study of PDR001 in Patients With Advanced Malignancies.

Start date: February 19, 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to characterize the safety, tolerability, Pharmacokinetics (PK), and antitumor activity of PDR001 administered intravenous (i.v.) as a single agent to Japanese patients.

NCT ID: NCT02383212 Completed - Advanced Cancer Clinical Trials

Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies

Start date: February 2, 2015
Phase: Phase 1
Study type: Interventional

This is a phase 1, open-label, multicenter, ascending-dose escalation study of cemiplimab, alone and in combination with other anti-cancer therapies in patients with advanced malignancies.